# Camlin Fine Sciences share price today (Camlin Fine Sciences Ltd, NSE: CAMLINFINE)

> Camlin Fine Sciences share price today: ₹74.15 at the NSE close on 4 November 2026, down 62.2% in a year. Camlin Fine Sciences (NSE: CAMLINFINE) is worth ₹1,425 crore, trades at a P/E of 66.7 and has closed between ₹74.15 and ₹196.01 over the past 52 weeks. > Camlin Fine Sciences Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CAMLINFINE · Chemicals - Others · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/camlin-fine-sciences-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹74.15 (−62.2% in a year)
- P/E: 66.7× (higher than 75% of the last 10 years)
- Revenue (Jun 2026): ₹520 Cr (+27.5% on a year ago)
- Profit (Jun 2026): −₹34.0 Cr
- Operating margin: 1.8% (−3.2 points on a year ago)
- ROCE: 5%, FY26

Biggest thing to watch: the P/E is higher than 75% of its own history, so the multiple has already done part of the work. ## What is the Camlin Fine Sciences share price today? Camlin Fine Sciences Ltd's share price was ₹74.15 at the close on 4 November 2026. It has been falling for 51 weeks. That is 39.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹74 and ₹196, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 15 weeks running. Over the last 11 years the share price moved −20% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 31 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Camlin Fine Sciences this quarter? Three changes stood out: lowest operating margin in 15 quarters, indian funds and insurers (DIIs) cut their stake for 3 quarters in a row and highest quarterly revenue in 15 quarters. 1. Lowest operating margin in 15 quarters Operating margin was 1.8% in the June 2026 quarter, against 5% a year earlier. Why: Margins fell because raw materials cost more, shipping took longer and cost more, and the company could not pass all the higher costs to customers. Next results: check whether Aroma and Performance Chemicals turn profitable in Q2 and whether the overall margin gets back to double digits in Q3. From the earnings call on 11 Aug 2026. 2. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row From 7.8% to 5.3% of the company by the September 2026 quarter. 3. Highest quarterly revenue in 15 quarters Revenue of ₹520 crore in the June 2026 quarter is the highest of the last 15 quarters. Why: Revenue hit a record because demand for blends stayed strong, especially in America. Next results: check whether blends sales grow by the planned 25 to 30 percent this year. From the earnings call on 11 Aug 2026. ## What are Camlin Fine Sciences' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Camlin Fine Sciences reported revenue of ₹520 crore, up 27.5% from ₹408 crore a year earlier, and a loss of ₹34.0 crore. ### Camlin Fine Sciences results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹520 crore | ₹408 crore | +27.5% |
| Profit | loss of ₹34.0 crore | loss of ₹11.0 crore | n/a |
| Earnings per share | ₹−1.65 | ₹−0.53 | n/a |
| Operating margin | 1.8% | 5.0% | −3.2 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Camlin Fine Sciences' management discussed these results on a call held on 11 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Camlin Fine Sciences share price history? Camlin Fine Sciences closed at ₹74.15 on 4 November 2026, down 62.2% from ₹196.01 a year earlier (7 November 2025) and down 54.4% over five years. Its highest weekly close since March 2016 was ₹327.53 on 27 June 2025. ### Camlin Fine Sciences share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹84.05 | −11.8% |
| 1 month ago · 1 Oct 2026 | ₹91.13 | −18.6% |
| 6 months ago · 8 May 2026 | ₹131.99 | −43.8% |
| 1 year ago · 7 Nov 2025 | ₹196.01 | −62.2% |
| 3 years ago · 3 Nov 2023 | ₹134.93 | −45.0% |
| 5 years ago · 4 Nov 2021 | ₹162.78 | −54.4% |
| 10 years ago · 4 Nov 2016 | ₹105.96 | −30.0% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹92.18 | −19.6% |
| Highest weekly close since March 2016 · 27 Jun 2025 | ₹327.53 | −77.4% |
| Lowest weekly close since March 2016 · 22 May 2020 | ₹35.27 | +110.2% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹196.01 | −62.2% |
| 52-week low (weekly close) · 4 Nov 2026 | ₹74.15 | 0.0% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 4 November 2026.)

## What is the latest news on Camlin Fine Sciences? 4 Nov 2026: Camlin Fine Sciences closed at ₹74.15, down 11.8% on the week and down 18.6% on the month. 11 Aug 2026: Camlin Fine Sciences held its results call for April to June 2026. Management guided: FY27 revenue ₹2,200-2,300 crore and operating profit ₹220-230 crore at 10-11% margin; average operating profit around ₹70 crore across the next three quarters. ### Earlier

- Results for April to June 2026: Revenue up 27.5% on a year earlier. ## What dividend does Camlin Fine Sciences pay? Camlin Fine Sciences has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. Not in its latest year. Camlin Fine Sciences Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 3 of its last 13 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Camlin Fine Sciences management say on the latest results call? On the call for April to June 2026, held on 11 August 2026, Camlin Fine Sciences' management guided: FY27 revenue ₹2,200-2,300 crore and operating profit ₹220-230 crore at 10-11% margin; average operating profit around ₹70 crore across the next three quarters. > “Obviously, the prolonged war situation can result in different outcomes, but if prices stabilize at their current levels, we should be looking at EBITDA in the range of 10-12% going forward.”
> Santosh Parab, CFO, on the call for April to June 2026

### What management guided

- FY28 operating margin 12-14% after normalization, supported by stable fixed costs. - Specialty Ingredients blends growth planned at 25-30% in FY27, with 20% described as the minimum. - Vanillin production approximately 3,000 tons in FY27; Q2 sales 500-600 metric tons and Q3 production and sales above 1,000 metric tons. - Aroma and Performance Chemicals to reach positive operating profit in Q2; consolidated operating margin to return to double digits in Q3. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/4720/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 11 August 2026.)

## What to watch in Camlin Fine Sciences' next results? When Camlin Fine Sciences reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2-to-Q3 consolidated margin recovery - check segment turns, raw-material pass-through and the planned normalization trajectory. - What to check (from the call)
- Q2-to-Q3 consolidated margin recovery - check segment turns, raw-material pass-through and the planned normalization trajectory. - Aroma campaign transition and Methyl Vanillin ramp - check positive operating profit and customer execution after the product switch. - Working-capital facility implementation - check funding availability, collections and reliance on supplier or dealer finance. - Diphenol plant economics - check alternate-use selection or restart progress as Chinese intermediates remain competitive. ## Which stock lists is Camlin Fine Sciences on? Camlin Fine Sciences is on one of our India lists: Penny stocks. [Penny stocks](https://www.sectoralpha.in/penny-stocks-india)

## Is Camlin Fine Sciences profitable? Camlin Fine Sciences Ltd posted a net loss of ₹34.0 Cr in the Jun 2026 quarter. Full-year FY26 profit was ₹24.0 Cr. Over 10 years profit has grown −4.0% a year on average. That loss is 6.5% of the quarter's revenue. The same quarter a year earlier lost ₹11.0 Cr. 10 of the last 12 reported quarters were loss-making. ## How much revenue does Camlin Fine Sciences make, and is it growing? Camlin Fine Sciences Ltd reported ₹520 Cr of revenue in the Jun 2026 quarter, +27.5% on the same quarter a year earlier. Over 10 years it has grown 13.4% a year on average. The last full year, FY26, came in at ₹1,723 Cr. The last four reported quarters add to ₹1,846 Cr. FY26 revenue was ₹1,723 Cr, +5.8% on the year before. Recent pace: the last four quarters grew +9.6% on average, against 13.4% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +9.4%, against +9.1% a year over the last 8 quarters (stabilising). ## How much of every ₹100 of sales does Camlin Fine Sciences keep? Camlin Fine Sciences Ltd's operating margin was 1.8% in the Jun 2026 quarter, 3.2 percentage points lower than the same quarter a year ago. Across 13 years it has been between 2.2% and 19.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −3.2 percentage points on the year while gross margin changed −3.4 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Camlin Fine Sciences' profit turning into cash? Over the last 3 years, 224% of Camlin Fine Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹82.0 Cr of operating cash against ₹24.0 Cr of profit. After ₹277 Cr of spending on assets, free cash was −₹195 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 224% of profit came in as cash: the cash cycle got 106 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Camlin Fine Sciences' cash go? Camlin Fine Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 78 days in FY26, down from 184 days in FY21. It spent ₹207 Cr on assets over the last 3 years. Customers take 79 days to pay, and stock sits for 199 days on average. At FY26 sales of ₹1,723 Cr, each day of that cycle ties up about ₹4.7 Cr, so roughly ₹368 Cr is tied up in the business at any time. FY26: customers took 79 days to pay and stock sat for 199 days, about 6.5 months of sales sitting as stock, for a full cycle of 78 days, shorter than FY21's 184. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 199 days. Customers pay about 79 days after that. Suppliers are paid at 200 days. Together that makes the 78-day cycle. Spending on assets: ₹207 Cr over the last 3 years, against ₹188 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹33.0 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Camlin Fine Sciences' P/E ratio, and how does it compare with its own history? Camlin Fine Sciences Ltd's P/E is 66.7×, near the high end of its own history: higher than 75% of past readings. Its usual P/E (the middle reading) is 47.9×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Where the price move came from: over 5 years the price moved −14.6% a year; about −11.8% a year came from earnings growth and about −2.8 percentage points from the multiple (the market paying less); over 10 years the price moved −3.5% a year; about −2.9% a year came from earnings growth and about −0.6 percentage points from the multiple (roughly no change). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 4.8% on reported income across 13 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Camlin Fine Sciences business getting better or worse? Camlin Fine Sciences Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Camlin Fine Sciences earn on its capital? Camlin Fine Sciences Ltd earned a ROCE of 5% in FY26. That is up from a low of 0% in FY18. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 1.4% net margin and 0.74× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 1.4% net margin × 0.74× asset turnover × 2.23× leverage (assets divided by equity) ≈ 2.3% on equity. The margin does its share; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 4.8% on reported income across 13 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Camlin Fine Sciences have too much debt? Camlin Fine Sciences Ltd had ₹720 Cr of borrowings against ₹1,041 Cr of equity in FY26, so its debt is 0.69× its equity. Its operating profit is 1 times its interest bill. Over 5 years borrowings went from ₹550 Cr to ₹720 Cr. Over the last 3 of those years it spent ₹207 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 4.8% on reported income across 13 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Camlin Fine Sciences shareholding pattern? Domestic institutions raised their stake in Camlin Fine Sciences Ltd by 1.1 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 5.3% of the company. Foreign institutions moved +0.1 points over the same period, to 0.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +1.1 points over 8 quarters, to 5.3%; Foreign institutions: +0.1 points over 8 quarters, to 0.9%; Promoters: +0.0 points over 8 quarters, to 48.0%. Why the owners changed: domestic institutions drove it (+1.1 points). They raised their stake step by step. ## How far is Camlin Fine Sciences from balance-sheet trouble? For Camlin Fine Sciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Camlin Fine Sciences rank in its industry? 21.3 out of 100, rank 4 of 4 in Chemicals - Others, with 64% of the evidence available. Camlin Fine Sciences Ltd scores 21.3 out of 100 against the 4 companies it is compared with in Chemicals - Others, ranking 4. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 8.3 + 3 + 10 + 0 = 21.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Camlin Fine Sciences compared with? Camlin Fine Sciences ranks 4 of 4 Chemicals - Others companies on the 4-Factor Sector Score, with 21.3 out of 100. 1. [Petro Carbon & Chemicals Ltd](https://www.sectoralpha.in/stocks/petro-carbon-chemicals-ltd) PCCL · breaking out · Too little evidence to rank firmly · 55% evidence 66.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.3/35 · Revenue n/a · Profit n/a · Operating margin change 8.6 points · 27% evidence Capital efficiency 14.1/25 · ROCE 14.1% · Operating margin 12% · 100% evidence Valuation 10.0/20 · P/E 41.4× · PEG n/a · 0% evidence Relative strength 20.0/20 · Lead over its industry 36.8% · Lead over NIFTY 500 58.1% · 1 year 129.4% · 100% evidence · 11 of 12 weeks ahead Exact sum: 22.3 + 14.1 + 10 + 20 = 66.4 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 2. [Shree Pushkar Chemicals & Fertilizers Ltd](https://www.sectoralpha.in/stocks/shree-pushkar-chemicals-fertilizers-ltd) SHREEPUSHK · breaking out · Evidence leans up · 97% evidence 58.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.0/35 · Revenue 15.6% · Profit 7.5% · Operating margin change 0 points · 100% evidence Capital efficiency 9.8/25 · ROCE 12.9% · Operating margin 11% · 100% evidence Valuation 11.7/20 · P/E 27× · PEG 0.42 · 85% evidence Relative strength 20.0/20 · Lead over its industry 37.1% · Lead over NIFTY 500 59.9% · 1 year 50.4% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17 + 9.8 + 11.7 + 20 = 58.5 · What this means: Relative strength against the index is 59.9%, and revenue and profit growth are weak. 3. [S H Kelkar & Company Ltd](https://www.sectoralpha.in/stocks/s-h-kelkar-company-ltd) SHK · quiet · Most evidence points down · 97% evidence 26.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.9/35 · Revenue 9.8% · Profit -52.4% · Operating margin change 0 points · 100% evidence Capital efficiency 7.7/25 · ROCE 5.8% · Operating margin 13% · 100% evidence Valuation 9.4/20 · P/E 36.7× · PEG 1.38 · 85% evidence Relative strength 0.0/20 · Lead over its industry -24.7% · Lead over NIFTY 500 -11.2% · 1 year -43.3% · 100% evidence · 9 of 12 weeks ahead Exact sum: 8.9 + 7.7 + 9.4 + 0 = 26 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. Camlin Fine Sciences Ltd this page CAMLINFINE · basing · Most evidence points down · 64% evidence 21.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.3/35 · Revenue 9.4% · Profit 100% · Operating margin change -3.2 points · 71% evidence Capital efficiency 3.0/25 · ROCE 4.8% · Operating margin 1.8% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 0.0/20 · Lead over its industry -42.2% · Lead over NIFTY 500 -31.4% · 1 year -57.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 8.3 + 3 + 10 + 0 = 21.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Chemicals - Others](https://www.sectoralpha.in/sectors/chemicals-others), all 4 compared on one page. ## Which companies are close to Camlin Fine Sciences in size? Camlin Fine Sciences is the 3rd largest of 4 Chemicals - Others companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Shree Pushkar Chemicals & Fertilizers and S H Kelkar & Company. Just below it: Petro Carbon & Chemicals. ### Chemicals - Others companies close in size

1. [Shree Pushkar Chemicals & Fertilizers Ltd](https://www.sectoralpha.in/stocks/shree-pushkar-chemicals-fertilizers-ltd) ₹1,949 crore
2. [S H Kelkar & Company Ltd](https://www.sectoralpha.in/stocks/s-h-kelkar-company-ltd) ₹1,735 crore
3. Camlin Fine Sciences Ltd ₹1,616 crore
4. [Petro Carbon & Chemicals Ltd](https://www.sectoralpha.in/stocks/petro-carbon-chemicals-ltd) ₹1,040 crore

[All 4 Chemicals - Others companies, largest first](https://www.sectoralpha.in/sectors/chemicals-others#all-companies)

### Companies close in size in other industries

1. [Shipping Corporation of India Land & Assets Ltd](https://www.sectoralpha.in/stocks/shipping-corporation-of-india-land-assets-ltd) ₹1,625 crore · Miscellaneous
2. [Greenpanel Industries Ltd](https://www.sectoralpha.in/stocks/greenpanel-industries-ltd) ₹1,622 crore · Plywood Boards/Laminates
3. Camlin Fine Sciences Ltd ₹1,616 crore
4. [BF Utilities Ltd](https://www.sectoralpha.in/stocks/bf-utilities-ltd) ₹1,612 crore · Power - Generation/Distribution
5. [RACL Geartech Ltd](https://www.sectoralpha.in/stocks/racl-geartech-ltd) ₹1,612 crore · Auto Ancillaries - Gears

## What else do people ask about Camlin Fine Sciences? ### What is Camlin Fine Sciences's share price today? Camlin Fine Sciences Ltd's share price is ₹74.15, −62.2% over the past year. The whole company is worth ₹1,425 Cr on the market. It is at its lowest price of the past 52 weeks (range ₹74 to ₹196), 39.7% below its 200-day average. The price has been falling for 51 weeks (as of 4 November 2026). ### What were Camlin Fine Sciences's latest quarterly results? Camlin Fine Sciences Ltd reported revenue of ₹520 Cr and a net loss of ₹34.0 Cr for the Jun 2026 quarter. Earnings per share were −₹1.65. The operating margin was 1.8%, 3.2 percentage points lower than a year earlier (as of 4 November 2026). ### What is Camlin Fine Sciences's market cap? Camlin Fine Sciences Ltd's market capitalisation is ₹1,425 Cr at a share price of ₹74.15. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Camlin Fine Sciences performing? Camlin Fine Sciences Ltd's share price has been falling for 51 weeks. Over the past 13 weeks it has done worse than the NIFTY 500, for 15 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Camlin Fine Sciences's share price go up? This page does not forecast Camlin Fine Sciences Ltd's share price. What it shows instead: the share price is ₹74.15, and it has been falling for 51 weeks. Its P/E of 66.7× is higher than 75% of its own last 10 years (as of 4 November 2026). ### Who owns Camlin Fine Sciences? Promoters own 48.0% of Camlin Fine Sciences Ltd, foreign institutions 0.9%, domestic institutions 5.3% and the public 45.7% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 1.1 percentage points over 8 quarters (as of 4 November 2026). ### Where is Camlin Fine Sciences in its business cycle? Camlin Fine Sciences Ltd's FY26 operating margin was 7.0%, against a 13-year range of 2.2% to 19.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 1.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Camlin Fine Sciences story? Biggest thing to watch: the P/E is higher than 75% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Camlin Fine Sciences a stock worth studying right now? What the numbers show: Camlin Fine Sciences Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Camlin Fine Sciences share price forecast for 2026? What management itself guided: FY27 revenue ₹2,200-2,300 crore and operating profit ₹220-230 crore at 10-11% margin; average operating profit around ₹70 crore across the next three quarters. ## Lists

- Penny stocks: https://www.sectoralpha.in/penny-stocks-india

This is research, not advice. We’re not SEBI-registered.